Navigation Links
Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions

LONDON and PHILADELPHIA, June 5 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the addition of Prous Science routes of synthesis (ROS) data to the Newport Horizon Premium and Newport Vision Premium solutions. An ROS focused search allows users to identify active pharmaceutical ingredients (APIs) according to an intermediate or reagent used, number of available routes or by patents referenced in a given route. Provided free of charge to current subscribers of the Premium systems, this new dataset, which provides an exciting compliment to the kilogram demand data released in March, enhances product targeting, business development and competitive intelligence by helping users to understand better the chemistry and manufacture of APIs.

The true or original manufacturing process used for a particular API is usually well protected by patents, making it challenging to devise equivalent, cheaper or more efficient processes without infringing on the originator's intellectual property. The new dataset will help to remedy this by providing extensive information for more than 2,500 APIs, consisting of:

-- Full chemical name

-- CAS number

-- Synthesis route diagram

-- Text commentary (with each step indexed to the diagram)

-- Patent references (linked to the patent page)

-- Intermediate chemicals and CAS numbers

-- Reagent chemicals and CAS numbers

-- Scientific journal references

"Understanding the 'recipe' of how a particular active ingredient is made -- or could be made -- is of vital importance to API manufacturers, generic companies and innovators," said Mike Chace-Ortiz, Senior Director, Product Strategy, Thomson Reuters. "By providing access to this important data, Newport Horizon Premium and Newport Vision Premium now allow our customers to gauge which patents are involved, what raw materials are needed, the cost and complexity of the process and whether specialized equipment or facilities must be bought or constructed."

For further information on Thomson Reuters API Intelligence solutions, visit:

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
2. Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines
3. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
4. Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare
5. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
6. Thomson Healthcare Announces Enhancements to Order Sets Solution
7. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
8. Thomson Scientific Introduces a New Quarterly Report Identifying the Movers and Shakers in the U.S. Generics Industry
9. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
10. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... During the National Family ... and held two webinars on topics of ‘Medical and Palliative Care Decisions,’ and ... . , With a loved one's diagnosis of mesothelioma, the closest ...
(Date:11/30/2015)... ... 2015 , ... Thermi™, a world leader in thermistor-regulated energy ... temperature controlled radiofrequency platform has received CE marking and may now be sold ... as a clinical endpoint. The technology has been available in the United ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... driverless vehicle experience this summer, ushering in a new era of publicly accessible ... and electric shuttle, will continue to offer guests an up-close look at the ...
(Date:11/30/2015)... Creek, Michigan (PRWEB) , ... November 30, 2015 , ... ... MI, the American Cancer Society held an annual fundraising event, a 5K walk known ... a holistic treatment center for substance abuse which is also located in Battle Creek, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... off its annual fundraising campaign to raise funds for its research, education, support, ... 10% of the organization’s annual funding. , The Mesothelioma Applied Research Foundation, which ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... the launch of Radiology Solutions, a fully integrated, ... Solutions comprises customized, data-driven practice management approaches that ... help radiology practices improve care delivery and reduce ... Radiological Society of North America Annual Meeting (RSNA) ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North ... and distribution of radiopharmaceuticals, announced that as of January ... Inc. (Zevacor Pharma). The decision to rebrand the company ... firm as well as its close relationship with Zevacor ... Illinois Health and Science (IHS). Peter ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, 2015 ... Public Research (the Institute) announced today that it ... a medical device start-up company with technology developed at ... based on publicly-funded research, and bridges early funding gaps ... -based universities and research institutions. ...
Breaking Medicine Technology: